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Summary 
This study investigates whether cell-derived glycosylphosphatidylinositol-linked complement control 
proteins CD55 and CD59 can be incorporated into HIVol virions and contribute to complement 
resistance.  Virus was prepared by transfection  of cell lines with pNL4-3,  and primary isolates 
of HIV-1 were derived from patients' PBMCs. Virus was tested for sensitivity to complement- 
mediated virolysis in the presence of anti-gp160 antibody. Viral preparations  from JY33 cells, 
which lack CD55 and CD59, were highly sensitive to complement.  HIV-1 preparations  from 
H9 and U937 cells,  which express low levels of CD55  and CD59,  had intermediate  to high 
sensitivity while other cell line-derived viruses and primary isolates of HIV-1 were resistant to 
complement-mediated  virolysis. Although  the primary isolates were not lysed, they activated 
complement as measured by binding to a complement receptor positive cell line.  While the pri- 
mary isolates were resistant to lysis in the presence of HIV-specific antibody, antibody to CD59 
induced lysis. Likewise, antibody to CD55 and CD59 induced lysis of cell line-derived virus. 
Western  blot  analysis  of purified  virus  showed bands  corresponding  to  CD55  and  CD59. 
Phosphatidylinositol-specific phospholipase C  treatment  of either cell line-derived or primary 
isolates of HIV-1 increased sensitivity to complement while incubation of sensitive virus with 
purified CD55 and CD59 increased resistance to complement.  These results show that CD55 
and CD59 are incorporated into HIV-1 particles and function to protect virions from complement- 
mediated destruction, and they are the first report of host cell proteins functioning in protection 
of HIV-1 from immune  effector mechanisms. 
S 
everal  studies  have  shown  that  host  cell  proteins  can 
be incorporated into the membranes of budding HIV-1 
virions.  The incorporated proteins include class I and II MHC 
and CDlla/CD18 (1--4). Some of these virion-associated mol- 
ecules may play a necessary functional role during cellular 
infection  or in resistance to immune  effector mechanisms. 
For example, host-derived receptors such as CDlla/CD18 on 
virions could facilitate adhesion of virus to target cells. Also, 
antibodies to MHC class I molecules can neutralize HIV (1), 
providing evidence for a critical role of these molecules in 
virus function.  Studies have shown,  however,  that  virions 
lacking class  I  (5)  or CD11a/CD18  (6) are still infectious. 
Thus, it has not yet been clearly demonstrated whether in- 
corporation of host cell proteins into virions can play a func- 
tional role in HIV-1 infection. 
High levels  of complement  and anti-HIV  antibody are 
present in the blood of infected persons,  and therefore one 
might predict that virions can be lysed by the membrane at- 
tack  complex  (MAC) 1 since  in  previous  in  vitro  studies, 
virus derived from the H9 cell line can be destroyed in this 
way (7,  8).  However, during  infection with  HIV-1, up to 
104-106 free virions per milliliter can be found in the plasma 
1 Abbreviations used in this paper: 3aria, 32-microglobulin; CR, complement 
receptor; GPI, glycosylphosphatidylinositol;  HI, heat inactivated; MAC, 
membrane attack protein; PI-PLC, phosphatidylinositol-specific  phospho- 
lipase C. 
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may be resistant to complement-mediated virolysis. The goals 
of this study were to determine whether complement con- 
trol proteins were incorporated by virions either from HIV- 
1-infected cell lines or from HIV-l-infected primary patient 
isolates,  and whether  the proteins functioned in resistance 
of virions  to complement  activation leading  to lysis. 
The results  of this  study indicate  that  glycosylphospha- 
tidylinositol (GPI)-linked proteins CD55 and CD59 are present 
on HIV-1 and provide resistance to complement-mediated lysis. 
This is the first demonstration  that virion-associated,  host 
cell-derived proteins function in the resistance of cell-free virus 
to immune  effector mechanisms. 
Materials and Methods 
Cells.  The T-lymphocytic H9 (HTB 176), the promonocytic 
U937 (CRL 1593), and the B-lymphoblastic CESS (TIB 190) cell 
lines were obtained from the American Type Culture Collection 
(Rockville, MD). The B-lymphoblastic AA-2 cell line (11) was ob- 
tained from the National Institutes of Health (NIH) AIDS Re- 
search and Reference Reagent Program (contributed by Michael 
Hershfield, NIH, Rockville, MD).  The B-lymphoblastic JY cell 
line and the mutant JY33 subline (deficient in GPI-linked proteins 
expression) were obtained from Dr. Timothy Springer (Dana Farber 
Cancer Institute, Boston, MA). The T-lymphoblastic HPB-ALL 
cell line (12) was also used in this study. Cells were grown in RPMI- 
1640 (Whittaker Bioproducts, Walkersville,  MD) supplemented 
with 10% heat-inactivated FCS (Hyclone Laboratories, Logan, UT). 
All cell lines were tested and found to be negative for mycoplasma 
contamination using the GEN-PROBE  |  Mycoplasma T. C. Rapid 
Detection System (Gen-Probe Inc., San Diego, CA). 
Complement,  Antibodies,  and Proteins.  Sera  from  HIV  anti- 
body-negative AB + donors were aliquoted and frozen at  -70~ 
for use as a source of complement. In some experiments, serum 
was heat inactivated (HI) at 56~  for 60 min to destroy comple- 
ment activity, and it was used as negative complement control. 
A  goat antiserum  to a baculovirus-derived HTLVmB (BH10) 
gp160 was obtained from the NIH AIDS Research and Reference 
Reagent Program (contributed by Robert Gallo, National Cancer 
Institute, Rockville, MD) and used as a source of anti-HIV anti- 
body. Polyclonal rabbit antisera to CD55 and CD59 were prepared 
as previously described (13, 14). All antisera used as sources of anti- 
body were HI at 56~  for 45 rain. The anti-CD55 and anti-CD59 
antisera were absorbed with JY33 mutant cells to remove reactivity 
against other cellular proteins. Mouse mAb to human CD55 (clone 
No. BRIC110) and CD59 (clone No. MEM43) antigens were ob- 
tained from Tago (Burlingame, CA) and Biodesign (Kennebunk, 
ME),  respectively,  and  horseradish  peroxidase-conjugated goat 
anti-mouse Ig was obtained from Amersham Corp.  (Arlington 
Heights, IL). Human CD55 and CD59 proteins were prepared from 
erythrocytes as described previously (15). Anti-CR2 mouse mAb 
(clone No. OKB7, IgG2b) was obtained from Ortho Diagnostic 
Systems,  Inc.  (Raritan,  NJ). 
Viruses.  A full-length, infection-competent HIV-1 clone pNL4-3 
(16) obtained from the NIH AIDS Research and Reagent Program 
(contributed by Malcolm Martin, NIH, Rockville, MD) was used 
to transfect seven human cell lines by a DEAE-dextran method (17). 
At 4 d posttransfection, cell superuatant was filtered (0.45 #m), 
aliquoted, and stored at  -70~  as cell-free virus stock. 
Five primary isolates of HIV-1 (JC50, MG47, MP49, PE51, and 
CJ48) were derived from asymptomatic HIV-l-infected subjects. 
Primary isolates were generated by coculture of PBMCs from in- 
fected and uninfected donors according to the method described 
by Gartner and Popovic (18). PBMCs from infected and uninfected 
subjects were stimulated separately for 3 d with phytohemagglu- 
tinin (5 #g/ml) and then cocultured at a 1:3 ratio in the presence 
of IL-2. Supernatants were harvested every 2nd d after the 7th d 
of culture, and aliquots stored at  -70~  as virus stocks. The level 
of p24 antigen in virus preparations was determined by ELISA 
(Coulter Co.,  Hialeah,  FL). 
Complement-mediated Virolysis.  To determine the sensitivity of 
HIV to complement, 20-#1  aliquots of virus containing  10 ng 
p24/ml were treated with complement or HI serum (final dilution 
1:10 unless otherwise specified) either alone or with anti-gp160 an- 
tiserum for 60 min at 37~  Virolysis resulting from antibody- 
mediated complement activation was calculated by measuring the 
release of HIV-1 p24 antigen by ELISA (Coulter Co.) (7). A min- 
imal background virolysis (0-4%) caused by complement alone was 
subtracted  from  each  value  obtained  from  complement  plus 
antibody-mediated lysis. Percent virolysis was calculated by the fol- 
lowing formula: [experimental lysis (no detergent)  -  untreated 
virus (background)] /  [experimental lysis (with detergent) -  un- 
treated virus]  x  100. 
To demonstrate the presence of CD55 and/or CD59 on HIV-1, 
virus preparations were treated with complement (final dilution 
1:10 unless otherwise specified) plus different dilutions of anti-CD55 
or anti-CD59 antiserum. 
Cell-binding  Assay for  Detecting Activation  of Complement  by 
HIV,  To determine the ability of HIV-1 primary isolates to acti- 
vate complement and thereby bind to complement receptor (CR)- 
positive HPB-ALL cells, aliquots of 30 #1 of each isolate (containing 
10 ng p24/ml) were incubated with complement or HI serum (final 
dilution 1:10) or complement plus anti-gp160 antiserum (final di- 
lution 1:50) for 60 rain at 37~  Virus was then added to a pellet 
of 1.5  x  106 HPB-ALL cells, mixed and incubated for 60 rain on 
ice. Cells were washed three times to remove unbound virus,  re- 
suspended  in 500 #1 of 0.5% Triton X-100 and cell lysates tested 
for the levels of cell-bound HIV-1 p24 antigen by ELISA. In other 
experiments designed to determine the mechanism of complement- 
mediated binding of HIV-1, HPB-ALL cells were pretreated with 
anti-CR2 antibody (OKB7) or isotype IgG control before incuba- 
tion with virus. 
Detection of CD55 and/or CD59 on HIV by Western Blotting.  Cell- 
free virus preparations were derived from pNL4-3 transfected HPB- 
ALL  cells. Virus  was  concentrated  approximately 100-fold  by 
ultracentrifugation at 140,000 g through 20% glycerol for 3 h and 
then purified by sucrose gradient (25-55% wt/wt) ultracentrifu- 
gation (275,000 g) for 18 h as described  previously (19, 20). The 
fractions which had an approximate density of 1.16 g/ml and con- 
tained the peak level of p24 were resuspended in lysis buffer (0.05 M 
Tris-HC1 pH 7.2, 0.15 M NaC1, 0.1% SDS, 1.0% deoxycholate, 
1  mM  phenyl  methylsulfonyl fluoride)  and  subjected  to  12% 
polyacrylamide-SDS (0.1%) gel electrophoresis (21) under non- 
reducing conditions.  A mock virus control was prepared from unin- 
fected HPB-ALL cell supernatants after the identical procedures 
of virus concentration and sucrose gradient purification. Purified 
CD55 and CD59 proteins were used as positive controls. The total 
amount of protein in the purified virus preparation was estimated 
by using the BCA protein assay reagent (Pierce Chemical Co., Rock- 
ford, IL). Proteins were electrotransferred to nitrocellulose mem- 
branes overnight at 4~  Membranes were incubated with mouse 
anti-CD55 or anti-CD59 mAb (final concentration = 0.75 #g/ml) 
washed and further incubated with goat anti-mouse Ig-conjugated 
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were detected using enhanced chemiluminescence detection reagents 
(Amersham Corp.,  Arlington  Heights,  IL) followed by exposure 
to x-ray film (Fuji Photo Film Co., Japan). 
Treatment of  HIV with Phosphatidylinositol-specific Phospholipase C 
(PI-PLC).  To remove GPI-linked proteins, HPB-ALL cell-derived 
virus or the primary  isolates MG47 or MP49 (20 #1 containing 
10 ng p24/ml) was incubated with PI-PLC (gift from Dr. M. Low, 
Columbia University, New York) (final concentration  = 1-6 U/ml) 
for 60 rain at 37~  and then PI-PLC was removed by ultracen- 
trifugation  through 20% glycerol. Virus was then incubated with 
complement  plus anti-gp160 antiserum  for 60 min at 37~  and 
virolysis was determined  by p24 ELISA. 
Reconstitution of Virus with CD55 and CD59 Protein.  To deter- 
mine the effect of reconstitution  of virions with exogenous com- 
plement control protein(s), viral preparations (20 #1 containing  10 
ng p24/ml) derived from U937 and JY33 cell lines or PI-PLC treated 
yiruses were incubated with or without CD55 or CD59 (final con- 
centration  =  3 #g/ml) for 60-90 min at 37~  Virus was then 
tested for sensitivity to virolysis in the presence of complement 
plus anti-gp160 antiserum. 
Results 
Sensitivity of Cell Line-derived  HIV to Complement.  Pre- 
vious studies had shown that HIV-1 derived from H9 cells 
was sensitive to complement-mediated virolysis in the pres- 
ence of antienvelope antibody (22).  To determine whether 
host cell components might affect the sensitivity of virus to 
complement in the presence of anti-gp160  antibody,  seven 
cell lines, each expressing different levels of complement control 
proteins  (7),  were transfected with  the infectious plasmid 
pNL4-3. This method of preparing virus was used to avoid 
the possibility that some substrains of virus might grow pref- 
erentially in different cell lines. Virions derived from the cells 
were  then  tested  for  sensitivity  to  complement-mediated 
virolysis. 
Viral preparations from the different transfected lines ex- 
hibited a broad range (2-99% virolysis) of sensitivity to com- 
plement in the presence of a 1:50 dilution of anti-gp160 anti- 
body. As previously reported (22), moderate levels (34%) of 
complement-mediated lysis of H9-derived HIV-1 occurred in 
the presence of antiviral  antibody (Fig.  1). Minimal lysis (3%) 
was observed with virus derived from JY cells that express 
high levels of CD55 and CD59, while substantially higher 
levels of lysis (72%) were observed with virus derived from 
mutant JY33 cells  that  are deficient in expression of GPI- 
linked proteins including CD55 and CD59 (Fig.  1). These 
results are consistent with the possibility that host cell GPI- 
linked proteins were incorporated into JY-derived virions and 
inhibited complement-mediated virolysis. This hypothesis is 
supported by the observation that H9-derived virus is inter- 
mediately sensitive to complement (Fig.  1) since our previous 
studies have shown that the H9 cell line has moderate to low 
levels of expression of CD55 and CD59 (7). Little or no virol- 
ysis (<1%) was observed with all cell line-derived virus in 
the presence of complement alone, except JY33-derived virus, 
where up to 4% lysis occurred. Additionally, antibody plus 
HI serum caused no lysis of virus  (<1%)  (not  shown). 
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Figure 1.  Sensitivity  of cell line--derived  HIV-1 to complement-mediated 
virolysis. Viral preparations (20 #1 containing 10 ng p24/ml) derived from 
pNL4-3-transfected  cell  lines, were  incubated with complement plus goat 
antiserum to gpl60. Viral preparations were also treated with growth 
medium and Triton X-100 to determine 0 and 100% lysis, respectively. 
Percentage  of virolysis  was calculated  by measuring the release  of p24 caused 
by complement activation compared to total p24 content released  by de- 
tergent. Each value represents the mean -+SD of three experiments. 
Viruses derived from HPB-ALL, AA-2, and CESS cells were 
resistant  to complement  (2-3%  lysis),  even at  the highest 
concentration  of anti-gp160  antibody (Fig.  1).  Since these 
cell lines express high levels of CD55 and CD59 (7), the com- 
plement resistance of virus derived from these cells could re- 
sult from incorporation of CD55 and CD59 into the virions. 
Interestingly, virus derived from the U937 cell line was highly 
sensitive to complement-mediated lysis, even in the presence 
of the highest dilution (1:300)  of anti-gp160 antibody (Fig. 
1).  The U937 cells express low levels of CD55 and CD59 
(7)  and may contain  a dysfunctional form of CD59  (23). 
Activation of Complement by Primary Isolates of HIV.  Since 
previous studies have shown that cell line-derived virus and 
primary isolates of HIV may have different properties,  five 
primary isolates of HIV-1, derived from five separate HIV- 
infected patients, were tested for their sensitivity to comple- 
ment in the presence of anti-gp160 antibody. All five isolates 
were resistant (3-7%  lysis)  to complement-mediated virol- 
ysis in the presence of high levels of anti-HIV antibody while 
virus derived from JY33 cells  was sensitive (Fig.  2).  Since 
the  primary  isolates  of  HIV-1  were  found  resistant  to 
complement-mediated lysis, it was possible that the anti-viral 
antibody used in these experiments did not bind to the intact 
virions.  To test this,  the primary isolates were assessed  for 
complement activation using a cell-binding  assay. Previous 
studies have shown that complement-treated virus will bind 
to CK2 + cells under conditions which do not favor virol- 
ysis (24). Cells were incubated with virus that was pretreated 
with complement, HI serum or complement plus anti-gp160 
antibody,  and  binding  to  CK2 +  HPB-ALL cells  was  as- 
sessed. All five isolates activated complement in the absence 
of antibody as has previously been observed with cell line-de- 
rived virus (24), but activation was greater in the presence 
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to determine the mechanism of complement-mediated binding 
of HIV-1 to HPBoALL cells,  it was observed that binding 
of three primary isolates (MG47, MP49, and CJ48) was in- 
hibited by 73-86% when HPB-ALL cells were preincubated 
with 10/zg/ml  of OKB7 antibody (data not shown), indi- 
cating that complement-mediated viral binding to HPB-ALL 
cells occurred via CR2. There was no inhibition of binding 
of HI serum-treated virus. Thus, while primary isolates ac- 
tivated complement in the presence of anti-gp160 antibody, 
these viruses were resistant  to lysis (Fig.  2). 
Association Of CD55 and CD59 with Cell Line-derived and 
Primary Isolates of HIV1.  To directly demonstrate whether 
CD55 and/or CD59 were associated with virions, viral prepa- 
rations were treated with complement plus antibody to CD55 
or CD59, and virolysis was assessed.  The antisera to CD55 
and CD59 that  were used in these experiments were both 
highly specific for the appropriate proteins, as determined by 
Western blot.  High levels of lysis (71%) of the JY cell-de- 
rived virus were observed after treatment with complement 
plus 1:60 dilution of anti-CD59 antibody (Fig. 4), indicating 
that CD59 protein was associated with virions. Anti-CD59 
antibody caused minimal lysis of the complement sensitive 
virus derived from the JY33 cell line,  which is deficient in 
CD59 (Fig.  4). In contrast to anti-CD59 induced lysis, low 
levels  of lysis (2%) of JY-derived virus was obtained with 
1:50  dilution  of anti-CD55  antibody (not  shown). 
Experiments with viruses from other cell lines such as HPB- 
ALL, AA-2,  CESS, and H9 gave similarly higher levels of 
lysis  (40-83%)  with  1:50 dilution  of anti-CD59  antibody 
(Table 1). A relatively low level of lysis (10%) of U937-derived 
virus was observed with anti-CD59 antibody. In contrast to 
anti-CD59-induced virolysis,  only 1-2% lysis of HPB-ALL-, 
AA-2-,  and CESS-derived viruses was observed with  1:50 
dilution of anti-CD55 antibody while H9 and U937-derived 
viruses were lysed (Table 1). These results clearly show that 
CD59 is associated with virions since it can act as a target 
for virolysis. Although lysis was lower, anti-CD55 also dearly 
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Figure  2.  Sensitivity  of primary  isolates  of HIV-1  to complement- 
mediated virolysis. Five primary isolates (20 ~1 containing 10 ng p24/ml) 
were incubated  with human complement plus anti-gpl60 antibody (final 
dilution 1:50), and the percentage of virolysis was calculated, pNL4-3-trans- 
fected JY33-derived virus was used as a positive lysis control. Results are 
representative  of three  separate experiments. 
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Figure 3.  Complement-mediated  binding of primary isolates of HIV-1 
to CR2§ cells. Aliquots (30/zl containing  10 ng p24/ml) of five primary 
isolates were  incubated  with complement (C), heat-inactivated  (HI) serum, 
or C plus anti-gpl60 antibody (final dilution - 1:50). The virus mixture 
was then incubated with 1.5  x  106 HPB-ALL cells for 60 min on ice. 
After washing, cells were lysed  with detergent and tested for cell-bound 
HIV-1 p24 by ELISA. Numbers above  the columns indicate fold increases 
of cell-bound  p24 relative to HI serum-treated virus. Results are represen- 
tative of three similar experiments. 
lysed virus from H9 and U937 cells and thus CD55 can be 
associated with virions. The lack of lysis ofJY-, HPB-ALL-, 
AA-2-, and CESS-derived virus preparations observed with 
anti-CD55 antibody could result either from lack of CD55 
or from a protective effect from other viral factor(s), including 
CD59. 
Complement-mediated virolysis (14-25%) of all five pri- 
mary isolates was achieved after treatment with anti-CD59 
antibody while low, but significant  (P <0.05, ANOVA) virol- 
ysis (2-5 %) of three out of five primary isolates was observed 
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Figure 4.  Virolysis of HIV-1 initiated by antibody to CD59. Virus de- 
rived from the pNL4-3-transfected JY and JY33 cell lines were incubated 
with complement plus serial dilutions of rabbit anti-CD59 antiserum  for 
60 min at 37~  and the percentage  of virolysis was determined.  Each 
value represents  the mean  _+SD of three  experiments. 
504  Role of CD55 and CD59 in Complement Resistance  of HIV-1 Table  1.  Complement-mediated  Lysis of Cell Line-derived HIV-1  Induced by Anti-CD55 and Anti-CD59 Antibody* 
Percentage of virolysis 
H9  U937  HPB-ALL  AA-2  CESS 
Anti-CD55  12  +  3.0  20  _+  14.0  1  _+  1.0  2  _+  1.0  1  _+  1.0 
Anti-CD59  40  _+  7.0  10  _+  4.0  83  +  3.0  39  _+  10.0  55  _+  8.0 
C  alone  1  _+  0.9  1  _+  0.6  0  _+  0.0  1  _+  1.0  0  +  0.0 
*  HIV-1 clone pNL4-3-transfected cell line-derived viruses were incubated with  complement (final dilution 1:5) either alone or with anti-CD55 
or anti-CD59 antibody (final concentration =  1:50). Release of core protein, p24 was measured by ELISA. Each value represents the mean _+ SD 
of three experiments. 
with  anti-CD55  (Fig.  5).  Virolysis induced by anti-CD55 
and anti-CD59  antibodies  directly demonstrated  that both 
GPI-linked proteins were associated with the primary isolate 
virions and suggested that their presence could be related to 
the resistance  of the virus  to complement. 
HIVol associated CD55 and CD59 were also assessed on 
Western blots of purified virus. Both proteins were detected 
on sucrose density gradient-purified virions (Fig. 6), which 
were derived from pNL4-3-transfected HPB-ALL cells. These 
cells express relatively high levels  of both CD55 and CD59 
(7),  and as shown above, virus from these cells was suscep- 
tible to lysis with anti-CD59 antibody but resistant to lysis 
with  anti-CD55.  In contrast,  no  CD55  was detected  in  a 
mock virus preparation from uninfected HPB-ALL cells, while 
a faintly detectable band was observed when blots were probed 
with anti-CD59. These results indicate that both CD55 and 
CD59  are present  on virions. 
Effects of  Exogenous CD55 and CD59 on HIV Complement 
Sensitivity.  Previous  studies  have shown that  exogenously 
Figure 5.  Virolysis  of HIV-1 primary isolates initiated by antibodies to 
CD55 and CD59. Aliquots of each isolate were incubated with comple- 
ment (final dilution 1:5) plus anti-CD59 or anti-CD55 antiserum (final 
dilution  =1:50). Each isolate was also incubated with complement plus 
anti-gp160 antibody (final dilution = 1:50). Percentage  of  virolysis  was de- 
termined as described in the legend to Fig. 1. Each value represents the 
mean  _+SD of three experiments. 
supplied GPI-linked proteins can become incorporated into 
lipid membranes and function in complement resistance of 
erythrocytes (13, 25). Since the above experiments suggested 
that complement resistance of HIV-1 may be at least in part 
caused by the presence of viral associated CD55 and CD59, 
complement-sensitive viruses from cells that are completely 
(JY33) or partially (U937) deficient in CD55 and CD59 (7) 
were incubated with exogenous CD59 and analyzed for their 
susceptibility  to complement-mediated  lysis.  The suscepti- 
bility of  JY33- and U937-derived viruses were substantially 
reduced after incubation with CD59 (Fig.  7 A). Similarly, 
susceptibility of U937-derived virus was also reduced after 
incubation with CD55 and CD59 (Fig. 7 B). Thus, comple- 
Figure 6.  Detection of CD55 
and CD59 on HIV-1  by Western 
blotting. Cell-flee HIV-1  derived 
from pNL4-3-transfected HPB- 
ALL cells and a mock virus prep- 
aration derived from uninfected 
HPB-ALL were purified by su- 
crose density gradient ultracen- 
trifugation. Proteins were sepa- 
rated on a 12% SDS-polyacryla- 
mide gel, electrotransferred onto 
a  nitrocellulose membrane, in- 
cubated with mouse monoclonal 
primary antibody, washed, and in- 
cubated with goat anti-mouse Ig- 
conjugated  horseradish  peroxidase. 
Protein bands were visualized by 
treating the blots with enhanced 
chemiluminescence detection re- 
agents before exposure to x-ray 
film. The upper panel is stained 
with monoclonal  anti-CD55 anti- 
body: Lanes I  and 3 contain 10 
#g of  protein of  purified virus and 
10 ng of purified CD55, respec- 
tively. Lane 2 contains a volume 
of  purified mock virus that corre- 
sponds to the volume  of  virus used 
in lane 1. The lower panel is stained with monoclonal anti-CD59 anti- 
body: lanes I  and 3 contain 1.2 #g of proteins of purified virus and 5 
ng of purified CD59, respectively. Lane 2 contains a volume of purified 
mock virus that corresponds to the volume of virus used in lane 1. 
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Figure 7.  Inhibition of complement-mediated lysis of HIV-1 after incu- 
bation with purified CD55 and CD59 proteins.  (A) Virus derived from 
pNL4-3 transfected JY33 and U937 cell lines were treated with or without 
CD59 (final concentration  =  3/~g/ml) for 60 min at 37~  JY33- and 
U937-derived viruses were then further incubated with complement  (final 
dilution =1:40 and 1:60, respectively) plus anti-gpl60 antibody (final di- 
lution  =  1:100) for 60 min at 370C.  The result  shown is representative 
of three similar experiments  and each value represents the mean  _+SD of 
duplicate values in the representative experiment. (B) U937-derlved virus 
was treated with or without CD55 or CD59 and susceptibility to gp160 
antibody-initiated complement lysis was assessed. Each value represents 
the mean  __SD of two experiments. 
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Figure 8.  Increased complement sensitivity  of HIV-1 primary isolates 
after treatment with PI-PLC. Aliquots of primary isolate MG47 were treated 
with buffer or buffer containing PI-PI.C (final concentration  =  6 U/ml) 
for 60 min at 37~  Virus was then further incubated with serial dilutions 
of complement plus anti-gp160 antibody (final dilution = 1:50) for 60 min 
at 37~  Each value represents  the mean  _+SD of three  experiments. 
plement were treated with PI-PLC and then ultracentrifuged 
through 20% glycerol to remove the PI-PLC. This treatment 
increased the complement sensitivity of these viral prepara- 
tions  from  1-4%  to  17-35%  virolysis  (Fig.  9).  The  PI- 
PLC-treated viruses were then incubated with exogenously 
purified CD55 and CD59.  As observed with  the sensitive 
cell line-derived viral preparations, sensitivity of all three PI- 
PLC-treated viruses to complement were markedly reduced 
by treatment  with  purified  CD59  (Fig.  9).  In contrast  to 
CD59, CD55 did not decrease virolysis although incubation 
with both proteins was more effective in protecting virions 
from lysis  than  CD59  alone. 
ment resistance of virus was increased by incorporation  of 
exogenous CD55  or CD59. 
Effects of  PI-PLC Treatment  and CD55/CD59 Reconstitution 
on HIV Complement Resistance.  Since CD55 and CD59 are 
covalently bound to cell membranes by a GPI linkage,  the 
MG47 primary isolate was treated with PI-PLC and analyzed 
for susceptibility to complement lysis in the presence of anti- 
gp160 antibody. Virolysis of PI-PLC-treated MG47 virus was 
substantially increased at all dilutions of complement com- 
pared to untreated control (Fig. 8), indicating that GPI-linked 
proteins, including CD55 and CD59, are present on virions 
and function in resistance of virus to complement. Cell lines 
H9 and HPB-ALL were also treated with PI-PI.C, and they 
were analyzed for the presence of CD55 and CD59.  Treat- 
ment with PI-PLC removed •  80-90% of CD55 and CD59 
(not  shown). 
The above experiments  indicated that  host cell comple- 
ment control proteins CD55 and CD59 are present on cell 
line-derived and primary isolates of HIV-1, and that cleavage 
of those proteins by PI-PLC could render the virus more sus- 
ceptible to complement. The HPB-ALL-derived and primary 
isolates of HIV-1 (MG47 and MP49) that are resistant to corn- 
40, 
30' 
v 
20 
10' 
Untreat 
[]  MG47 
￿9  HPBpNL4-3 
[]  MP49 
,t 
PI*Lc  cI;59  cnss c059;eD55 
Figure 9.  Treatment  with PI-PLC increases complement sensitivity of 
primary HIV-1 isolates and a cell line-derived virus, and incubation  with 
CD55 or CD59 restores complement resistance, pNL4-3-tramfected  HPB- 
ALL-derived virus and two primary isolates of HIV-1 (MG47 and MP49) 
were treated with PBS or PI-PLC (final concentration  =  1.0 U/ml) for 
60 min at 37~  and then ultracentrifuged  through 20% glycerol to re- 
move PI-PLC. Viruses were then further incubated with CD55 or CD59 
or both (final concentration =  3 tzg/ml) for 90 min at 37~  Viral sensi- 
tivity to virolysis was analyzed after incubation  with complement plus 
anti-gp160  antiserum.  Each value represents the mean  _+SD of two ex- 
periments. 
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Complement control proteins constitute a mechanism that 
regulates a balance between the destruction of foreign or- 
ganisms and the protection of the host against complement- 
mediated injury (26, 27). Complement pathway regulators 
such as decay accelerating factor (DAF, CD55) prevent for- 
mation of C3/C5 convertases and accelerate their decay (28), 
while cell surface membrane cofactor protein, (MCP, CD46) 
complement receptor type 1 (CD35), and plasma constitu- 
ents factor H and C4 binding protein act as cofactors for Factor 
I-mediated cleavage of C3b and C4b (29, 30).  The mem- 
brane inhibitor of reactive lysis (MIRL, CD59) inhibits for- 
mation of the cytolytic MAC (13, 31, 32). Of these inhibi- 
tors,  CD55 and CD59 are anchored to the cell membrane 
by a GPI linkage. The current study was undertaken to in- 
vestigate whether HIV-1 virions incorporate CD55 and CD59 
into their membrane and thereby gain protection from MAC- 
mediated lysis. 
Initial experiments performed in this study were consis- 
tent with the hypothesis  that host cell-derived  CD55 and 
CD59 were present on virions since there was an inverse rela- 
tionship between expression of those proteins by host cells 
and complement sensitivity of virus from those cells. Thus, 
virus from  JY33 cells that lacked CD55 and CD59 were highly 
sensitive to complement, virus from H9 cells that expressed 
low levels of CD55 and CD59 had intermediate sensitivity 
to complement, and virus from cells that expressed high levels 
of CD55 and CD59,  including JY, HPB-ALL,  AA-2, and 
CESS, were resistant to lysis. The exception to this pattern 
was virus derived from U937  cells, which expressed levels 
of CD55 and CD59 similar to H9 cells but was highly sensi- 
tive to lysis. The reason for the high susceptibility of U937- 
derived virus could result from one or more factors including 
(a) low expression of CD55 and CD59 by U937; (b) possible 
expression of nonfunctional CD59 by U937 (23); (c) low ex- 
pression of other regulators of complement activation such 
as CD46 that could be incorporated into virions; or (d) ex- 
pression of higher levels of gp160 on virions from U937. Flow 
cytometric analysis, however, indicated  that CD46 expres- 
sion was  similar  among H9, JY33,  and U937  cells (not 
shown), suggesting that differences in CD46 levels on virus 
may not account for the differing complement sensitivity of 
virus derived from these cells. The mechanism responsible 
for sensitivity of U937 virus is currently being investigated. 
The results obtained in this study clearly demonstrate the 
presence of  both CD55 and CD59 on virions since immuno- 
blots showed bands for both CD55  and CD59.  Addition- 
ally, antibody to CD59 induced substantial lysis of virions 
from JY and other cell lines, as well as from primary isolates. 
A somewhat different lysis pattern was obtained with anti- 
body to CD55. This antiserum induced significant lysis of 
virions from U937 and H9 cells expressing low levels of CD55 
and CD59, and essentially no lysis of virions from JY, HPB- 
ALL, AA-2, and CESS cells expressing high levels of CD55 
and CD59 and low lysis of primary isolates of HIV-1. The 
difference  in degree of lysis caused by the anti-CD55 and anti- 
CD59 antisera could result from several  conditions including 
(a) a higher relative efficacy of CD59 in viral resistance to 
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lysis coupled with an ability of anti-CD59 antibody to serve 
as an activator of complement as well as an inhibitor of CD59 
function; (b) general lower expression of CD55 than CD59 
by virus; or (c) lower potency of the anti-CD55 antiserum. 
As described above, it was shown that primary isolates were 
resistant to complement-mediated lysis, at least in part be- 
cause of the presence of CD55 and CD59 on the virions, 
and yet-activated complement. It has been shown that after 
activation of complement, the breakdown products C3dg and 
iC3b form on intact virions. As has been previously reported, 
instead of viral inactivation, complement can enhance infec- 
tion of HIV-1 by enhancing binding of  virions to cells through 
interaction with complement receptors (24, 33-35). This can 
occur under the condition of high levels of complement in 
the absence of antibody or low levels of complement in the 
presence of antibody. Thus, GPI-linked proteins on virions 
may facilitate enhancement of HIV-1 infection by inducing 
resistance to virolysis. 
Both CD55 and CD59 proteins are anchored by GPI linkage 
and treatment of complement-resistant  virus with PI-PLC 
conferred a phenotypic change to complement sensitive virus. 
This supports the hypothesis that the complement resistance 
of HIV-1 resulted from the presence of host cell-derived, GPI- 
linked complement regulatory proteins  on the virions. Al- 
though complement sensitivity of PI-PLC-treated viruses was 
increased by more than fivefold in the presence of anti-gp160 
antibody, the level of sensitivity obtained was still low com- 
pared to sensitive virus derived from the mutant JY33 line, 
which lacks both CD55 and CD59.  This difference could 
be caused by incomplete removal of GPI-anchored proteins 
from virions by PI-PLC since by using flow cytometry we 
determined that the PI-PLC removed most (80-90%) but 
not all GPI-linked proteins  on cells. Susceptibility of GPI- 
linked proteins  to PI-PLC has been shown to vary due to 
several factors including the type of cells or surfaces to which 
proteins are attached (36), interactions with other membrane 
components, or modification of the structure of the GPI an- 
chor (37). 
An important observation in this study was that treatment 
of complement-sensitive or PI-PLC-treated viruses with ex- 
ogenous human CD55 and/or CD59 increased complement 
resistance. Similar results have  been observed using other ex- 
perimental models. For example, treatment of rat oligoden- 
drocytes  with human erythrocyte-derived  CD59 (38) or guinea 
pig erythrocytes with seminal plasma-derived CD59 (39) pro- 
tected cells from lysis  by human complement. Similarly,  recon- 
stitution of erythrocytes from patients with paroxysmal noc- 
turnal hemoglobinuria with purified CD55 (25) or CD59 
(13) ameliorated their complement sensitivity. 
Earlier studies have reported that animal retroviruses are 
destroyed by human complement in the absence of antiviral 
antibody  (40-42),  whereas human retroviruses  HIV  and 
human T cell leukemia virus are resistant to complement (19, 
43). The results of the current study suggest that the resis- 
tance of HIV and human T cell leukemia virus may result 
in part from the incorporation of host complement regula- 
tory proteins  into the virions. It is possible that the sensi- 
tivity of animal retroviruses grown in nonhuman cells could result in part from the low regulatory activity of the animal 
complement control proteins  against  human complement 
(32,  44). 
This study indicated that CD55 and CD59 retained their 
complement regulatory effect while incorporated on the sur- 
face of HIV-1 virions. Several other cellular proteins, including 
MHC class I and class II, 32-microglobulin (fl2m), as well 
as  the  adhesion  molecules  leukocyte  function-associated 
antigen-1 and intercellular adhesion molecule-1 associated with 
HIV virions have also been suggested to have functional effects 
on viral infectivity, and antibody to some of these molecules 
can neutralize virions (1). However, a recent report (5) showed 
that incorporation of MHC class I molecules are not essen- 
tial for the infectivity of H IV, and that neutralization of  virus 
by antibody to this molecule may be caused by a steric blocking 
effect. Similarly, it has been suggested that the association 
of •2m  with cytomegalovirus allows the virus to evade neu- 
tralization by anti-viral immune response (45). Alternatively 
this effect may again be simply due to nonspecific blocking 
of the neutralizing determinant of the virions by 32m.  In 
this regard, the current study provides evidence that cellular 
proteins incorporated on the virions remain functionally ac- 
tive and directly contribute resistance to immune-mediated 
attack.  Whether this function would be essential for viral 
replication in vivo is not known. 
In conclusion, this report documents that host cell com- 
plement control proteins CD55 and CD59 are incorporated 
into HIV-1 virions and contribute to the viral resistance to 
complement, and,  as such,  this is the first report to show 
a functional role for host cell-derived proteins. This mecha- 
nism is likely to contribute to the escape of virions from the 
complement system in vivo. 
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